24 / 32
TATTON: osimertinib + savolitinib for EGFR-
mut & MET-amp NSCLC post EGFR TKI
100
75
50
25
0
-25
-50
-75
-100
Best % change from baseline
in
tumour
lesion size
Prior 3rd Gen T790M directed EGFR-TKI
No prior 3
rd
gen EGFR-TKI, T790M
+
No prior 3
rd
gen EGFR-TKI, T790M-
Objective response
rate,
n (%)
Prior 3
rd
Gen
T790M directed
EGFR-TKI
(n = 30)
No prior 3
rd
Gen T790M directed
EGFR-TKI
Total
(n = 64)
T790M+
(n = 11)
T790M-
(n = 23)
ORR
†
10 (33)
6 (55)
14 (61)
30 (47)
n = 64
Ahn – WCLC 2017
Ahn IASLC 17